MGC Pharmaceuticals Ltd
(ASX:MXC), seems to be making progress with its Australian Medical Cannabis Strategy – which focuses on the benefits of medical cannabis to treat children with severe epilepsy.
MGC has appointed Professor Uri Kramer, an Israeli expert in pediatric neurology, to its Strategic Advisory Board. The company says Prof. Kramer will direct the development of its clinical trial programs in Australia and Europe.
The company also says it has teamed up with the University of Sydney to begin the process of stakeholder engagement with the Australian federal government, state governments, medical professionals, academics and industry participants.
This follows the Victorian government recently passing legislation which will allow children with severe epilepsy to be treated with medical cannabis – on compassionate grounds.
MGC reported a net loss of $3.4 million at 31 December 2015.
